<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2717">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496313</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00097</org_study_id>
    <secondary_id>2011-004701-24</secondary_id>
    <nct_id>NCT01496313</nct_id>
  </id_info>
  <brief_title>To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer</brief_title>
  <official_title>An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day
      or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It
      will also help the investigators understand the side effects of different doses in these
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And
      Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or
      Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator</measure>
    <time_frame>Randomisation to week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR=proportion of patients with a best response of complete or partial response as per Response Evaluation Criteria in Solid Tumors(RECIST)1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response</measure>
    <time_frame>Randomisation to week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (RECIST 1.1) by Treatment Arm</measure>
    <time_frame>Randomization to Week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Objective Response (RECIST 1.1) by Treatment Arm</measure>
    <time_frame>Randomization to Week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm</measure>
    <time_frame>Randomization to Week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Vandetanib in the Bloodstream (Cmax) for Patients by Treatment Arm.</measure>
    <time_frame>Week 3 to week 60 (maximum)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>300mg vandetanib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg vandetanib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg vandetanib</intervention_name>
    <description>Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment
Dosing with unblinded study treatment can continue until 24 months after patient was randomised.
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.</description>
    <arm_group_label>300mg vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg vandetanib</intervention_name>
    <description>Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg
Dosing with unblinded study treatment can continue until 24 months after patient was randomised
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.</description>
    <arm_group_label>150mg vandetanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent from Female or male patients aged 18 years and over. Previously
             confirmed histological diagnosis of unresectable, locally advanced or metastatic,
             hereditary or sporadic MTC Objective disease progression within the previous 14
             months prior to enrolment, and/or

          -  Have one or more symptoms that the Investigator believes to be related to the
             patient's MTC.

          -  World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG)
             Performance status 0-2.

          -  Has measurable disease (at least one lesion, not irradiated within 12 weeks of study
             randomisation, with longest diameter more or equal 10mm (lymph nodes minimum more or
             equal 15 mm) with CT or MRI).

          -  Lesions must be amenable to accurate and repeat measurement.

        Exclusion Criteria:

          -  Prior treatment (major surgery, radiation therapy, chemotherapy, or other
             investigational drugs) received within 28 days before randomization.

          -  Abnormal liver function tests (bilirubin more than 1.5xULRR, and ALT, AST, or ALP
             more than 2.5xULRR or 5.0xULRR if related to liver metastases).

          -  Significant cardiac conditions or events such as reduced cardiac functions,
             symptomatic cardiac arrhythmia requiring treatment, congenital long QT syndrome,
             history of drug-induced QT prolongation, or QTcF correction unmeasurable or more than
             450 ms.

          -  Abnormal electrolytes such as potassium, magnesium and calcium, or abnormal organ
             functions such as decreased creatinine clearance.

          -  For women only - currently pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella Mariani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AZ MSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mimi I Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greater London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyne &amp; Wear</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1434&amp;filename=D4200C00097_Study_Synopsis.pdf</url>
    <description>D4200C00097_CSR_Synopsis.pdf</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 27, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2011</firstreceived_date>
  <firstreceived_results_date>April 1, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medullary thyroid cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>thyroid cancer</keyword>
  <keyword>carcinoma of the thyroid</keyword>
  <keyword>receptor tyrosine kinase inhibitor</keyword>
  <keyword>VEGFR</keyword>
  <keyword>Unresectable locally advanced thyroid cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In total, 93 patients were enrolled out of which 81 patients were randomised to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib 150 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
        <group group_id="P2">
          <title>Vandetanib 300 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib 150 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
        <group group_id="B2">
          <title>Vandetanib 300 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.2" spread="15.24"/>
                <measurement group_id="B2" value="52.7" spread="15.42"/>
                <measurement group_id="B3" value="52.5" spread="15.24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&gt;=18 to &lt;40 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=40 to &lt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 to &lt;75 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=75 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator</title>
        <description>ORR=proportion of patients with a best response of complete or partial response as per Response Evaluation Criteria in Solid Tumors(RECIST)1.1</description>
        <time_frame>Randomisation to week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial response (PR), at least a 30% decrease in the sum of diameters of target lesions; ORR = CR + PR</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator</title>
            <description>ORR=proportion of patients with a best response of complete or partial response as per Response Evaluation Criteria in Solid Tumors(RECIST)1.1</description>
            <units>Proportion of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.20" lower_limit="0.105" upper_limit="0.348"/>
                  <measurement group_id="O2" value="0.29" lower_limit="0.176" upper_limit="0.445"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Objective Response</title>
        <time_frame>Randomisation to week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per RECIST v1.1 for target lesions: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions; Progressive disease (PD), at least 20% increase in the sum of diameters of target lesions; Stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Best Objective Response</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Progressive disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-evaluable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response (RECIST 1.1) by Treatment Arm</title>
        <time_frame>Randomization to Week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per RECIST v1.1 for target lesions: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions; Progressive disease (PD), at least 20% increase in the sum of diameters of target lesions; Stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Objective Response (RECIST 1.1) by Treatment Arm</title>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.8" lower_limit="2.8" upper_limit="11.2"/>
                  <measurement group_id="O2" value="8.4" lower_limit="3.0" upper_limit="11.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Objective Response (RECIST 1.1) by Treatment Arm</title>
        <time_frame>Randomization to Week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per RECIST v1.1 for target lesions: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions; Progressive disease (PD), at least 20% increase in the sum of diameters of target lesions; Stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Objective Response (RECIST 1.1) by Treatment Arm</title>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.2" lower_limit="2.8" upper_limit="11.2"/>
                  <measurement group_id="O2" value="4.4" lower_limit="2.8" upper_limit="11.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm</title>
        <time_frame>Randomization to Week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per RECIST v1.1 for target lesions: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions; Progressive disease (PD), at least 20% increase in the sum of diameters of target lesions; Stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm</title>
            <units>% change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.8" spread="29.24"/>
                  <measurement group_id="O2" value="-17.5" spread="18.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.0" spread="19.51"/>
                  <measurement group_id="O2" value="-24.9" spread="22.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-16.7" spread="24.33"/>
                  <measurement group_id="O2" value="-29.1" spread="22.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-20.7" spread="23.56"/>
                  <measurement group_id="O2" value="-30.6" spread="25.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up RECIST assessment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-51.0" spread="0"/>
                  <measurement group_id="O2" value="-11.4" spread="67.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Disc. of blinded vandetanib</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.9" spread="27.98"/>
                  <measurement group_id="O2" value="-27.3" spread="29.58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Vandetanib in the Bloodstream (Cmax) for Patients by Treatment Arm.</title>
        <time_frame>Week 3 to week 60 (maximum)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients who received at least 1 dose of vandetanib and for whom quantifiable plasma concentration data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 150 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Vandetanib 300 mg</title>
            <description>Oral blinded tablet, taken once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentration of Vandetanib in the Bloodstream (Cmax) for Patients by Treatment Arm.</title>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 3 (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="428.6" spread="140.71"/>
                  <measurement group_id="O2" value="786.2" spread="243.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 (Day 56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510.5" spread="206.50"/>
                  <measurement group_id="O2" value="941.0" spread="249.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 (Day 84)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="561.4" spread="215.66"/>
                  <measurement group_id="O2" value="969.9" spread="396.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 (Day 168)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="549.7" spread="189.62"/>
                  <measurement group_id="O2" value="1017.7" spread="330.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinuation of blinded vandetanib</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="536.8" spread="225.34"/>
                  <measurement group_id="O2" value="964.0" spread="357.30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib 150 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
        <group group_id="E2">
          <title>Vandetanib 300 mg</title>
          <description>Oral blinded tablet, taken once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>MILLER FISHER SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>KERATOPATHY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabriella Mariani, MD</name_or_title>
      <organization>AstraZeneca, SG8 6HB</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
